Universitäres Centrum für Tumorerkrankungen Mainz (UCT Mainz)
Klinisch orientierter Schwerpunkt / Johannes Gutenberg-Universität Mainz
Smyth, Elizabeth C.; Moehler, Markus
Pembrolizumab in First-line Gastric Cancer: Win, Lose, or Draw?JAMA ONCOLOGY. Bd. 6. H. 10. 2020 S. 1539-1541
Waldschmidt, D.; El-Khoueir, A. B.; Kim, R. D. et al.
Phase 1b study of regorafenib (REG) plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC)ONCOLOGY RESEARCH AND TREATMENT. Bd. 43. H. SUPPL 4. 2020 S. 123-123
El-Khoueiry, Anthony B.; Kim, Richard D.; Harris, William P. et al.
Phase Ib study of regorafenib (REG) plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC)JOURNAL OF CLINICAL ONCOLOGY. Bd. 38. H. 4. 2020
Bergholz, Liana M.; Grimminger, Peter; Dikeoulia, Elsa et al.
Pilot Study on Malnutrition and DNA Damage in Patients with Newly Diagnosed Gastrointestinal Tumors: Is DNA Damage Reversible by Early Individualized Nutritional Support?JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES. Bd. 29. H. 4. 2020 S. 569-577
Roldán, DB; Grimmler, M; Hartmann, C et al.
PLAC1 is essential for FGF7/FGFRIIIb-induced Akt-mediated cancer cell proliferation.ONCOTARGET. Bd. May, 19. H. 11(20). 2020 S. 1862-1875
Van der Kooi, A-L.; Van Dijk, M.; Broer, L. et al.
Possible Modification of BRSK1 on the Risk of Alkylating Chemotherapy-Related Reduced Ovarian FunctionPEDIATRIC BLOOD & CANCER. Bd. 67. 2020 S. S25-S26
Grimminger, Peter Philipp; van der Sluis, Pieter Christiaan; Fetzner, Ulrich Klaus
Postoperative C-reactive Protein: Focus on Patients After Esophagectomy and Clear Guidance for Daily Praxis ReplyANNALS OF THORACIC SURGERY. Bd. 110. H. 3. 2020 S. 1098-1098
Kulik, Laura; da Fonseca, Leonardo G.; He, Aiwu Ruth et al.
Potential Impact of IMbrave150 Results in the Evolving Treatment Landscape of Advanced Hepatocellular Carcinoma: A Multidisciplinary Expert OpinionJOURNAL OF HEPATOCELLULAR CARCINOMA. Bd. 7. 2020 S. 423-433
Schulz, Christoph; Heinemann, Volker; Heinrich, Kathrin et al.
Predictive and prognostic value of magnesium serum level in FOLFIRI plus cetuximab or bevacizumab treated patients with stage IV colorectal cancer: results from the FIRE-3 (AIO KRK-0306) studyANTI-CANCER DRUGS. Bd. 31. H. 8. 2020 S. 856-865
Stockinger, M.; Karle, H.; Metz, J. et al.
PREFERE Study on Prostate Cancer with low or early intermediate Risk. Quality Control of the Permanent Seed ImplantationSTRAHLENTHERAPIE UND ONKOLOGIE. Bd. 196. H. SUPPL 1. 2020 S. S45-S46